Aviceda Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aviceda Therapeutics's estimated annual revenue is currently $4.3M per year.
- Aviceda Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Aviceda Therapeutics has 28 Employees.
- Aviceda Therapeutics grew their employee count by 8% last year.
Aviceda Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder, CEO & President, Executive Board Director | Reveal Email/Phone |
2 | Scientific Co-Founder | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | Chief Clinician and Scientist Oncology | Reveal Email/Phone |
6 | Chief Development Officer & SVP | Reveal Email/Phone |
7 | Director, Nanoparticle Formulations and Analytical Development (CMC-Head) | Reveal Email/Phone |
8 | Senior Director / Head Biology | Reveal Email/Phone |
9 | Executive Assistant; Office Manager | Reveal Email/Phone |
10 | Senior Research Associate / Lab Manager | Reveal Email/Phone |
Aviceda Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Aviceda Therapeutics?
Aviceda Therapeutics is a late-stage, pre-clinical stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic degenerative, oncologic, fibrotic, and immuno-inflammatory diseases. A combination of cutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation. Aviceda has combined the power of our glycobiology and glycochemistry platform with our proprietary nanoparticle technology to engineer transformative disease modifying medicines. Using our cell-based high-throughput screening (HTS) platform, we can rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. Optimized ligands are tethered to our modular biodegradable nanoparticles using high precision conjugation chemistry to form biologically stable linkages. Our GCT nanoparticles are designed for optimal therapeutic durability and maximum therapeutic efficacy while utilizing the most effective route of administration. Aviceda’s platform is highly adaptable, enabling the development of a broad spectrum of therapeutics for immuno-inflammatory indications with large unmet medical needs.
keywords:N/AN/A
Total Funding
28
Number of Employees
$4.3M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.3M | 28 | 8% | N/A |
#2 | $2.8M | 28 | N/A | N/A |
#3 | $4M | 28 | N/A | N/A |
#4 | $2.7M | 28 | N/A | N/A |
#5 | $2.8M | 28 | N/A | N/A |